Literature DB >> 30093507

Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.

Nicoletta Riva1, Kevin Vella2, Kieron Hickey3, Lorenza Bertù4, Daniel Zammit2, Silvana Spiteri2, Steve Kitchen3, Michael Makris3, Walter Ageno4, Alex Gatt5,2.   

Abstract

BACKGROUND: The diagnostic algorithm for venous thromboembolism (VTE) currently involves a composite of pre-test probability, D-dimer and imaging. Other laboratory tests, however, may assist in the identification of patients with VTE. AIM: To assess the accuracy of different coagulation tests (D-dimer, thrombin generation, phospholipid-dependent (PPL) clotting time, soluble P-selectin (sP-selectin)) as biomarkers of acute VTE.
METHODS: Random samples arriving at the Coagulation Laboratory at Mater Dei Hospital (Msida, Malta) from the Accident and Emergency Department with a request for D-dimer measurement were collected between August 2015 and February 2016. The following tests were performed: Innovance D-dimer (Siemens Healthcare Diagnostics), HemosIL D-dimer HS (Instrumentation Laboratory), thrombin generation (using the calibrated automated thrombogram), STA Procoag PPL (Diagnostica Stago) and sP-selectin (Affymetrix; eBioscience). VTE was objectively confirmed by compression ultrasonography, CT pulmonary angiography or ventilation/perfusion lung scan.
RESULTS: 100 samples were collected (33 with VTE). A strong positive linear correlation was found between the two D-dimer tests (r=0.97, p<0.001). Patients with VTE showed significantly higher sP-selectin concentrations compared with patients without VTE (75.7 ng/mL vs 53.0 ng/mL, p<0.001). In the random forest plot, the two D-dimer assays showed the highest variable importance, followed by sP-selectin. A sP-selectin cut-off of 74.8 ng/mL was associated with 72.7% sensitivity and 78.2% specificity for acute VTE in our cohort.
CONCLUSION: Our results confirmed D-dimer as the main biomarker of VTE and speculated a role for sP-selectin. The impact of thrombin generation was limited and no role emerged for the PPL clotting time. These observations need to be confirmed in large management studies. © Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  biomarkers; diagnosis; venous thromboembolism

Mesh:

Substances:

Year:  2018        PMID: 30093507     DOI: 10.1136/jclinpath-2018-205293

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  5 in total

1.  Procoagulant Disorders in Patients with Newly Diagnosed Pancreatic Adenocarcinoma.

Authors:  Renata Talar-Wojnarowska; Małgorzata Woźniak; Anna Borkowska; Katarzyna Cypryk; Marek Olakowski; Ewa Małecka-Panas
Journal:  Medicina (Kaunas)       Date:  2020-12-09       Impact factor: 2.430

2.  Plasma procoagulant phospholipid clotting time and venous thromboembolism risk.

Authors:  Cathrine Ramberg; Line Wilsgård; Nadezhda Latysheva; Sigrid K Brækkan; Kristian Hindberg; Timofey Sovershaev; Omri Snir; John-Bjarne Hansen
Journal:  Res Pract Thromb Haemost       Date:  2021-12-20

3.  Identification of four hub genes in venous thromboembolism via weighted gene coexpression network analysis.

Authors:  Guoju Fan; Zhihai Jin; Kaiqiang Wang; Huitang Yang; Jun Wang; Yankui Li; Bo Chen; Hongwei Zhang
Journal:  BMC Cardiovasc Disord       Date:  2021-12-03       Impact factor: 2.298

4.  Opportunistic Diagnosis of Extensive Pulmonary Embolus Following "COVID-19 Blood Battery" in Very Frail Older Patients.

Authors:  M M C O'Brien; J M McLoughlin; E C Mulkerrin
Journal:  J Nutr Health Aging       Date:  2020       Impact factor: 4.075

5.  D-dimer, thrombin generation, and risk of a first venous thrombosis in the elderly.

Authors:  Huijie Wang; Frits R Rosendaal; Mary Cushman; Astrid van Hylckama Vlieg
Journal:  Res Pract Thromb Haemost       Date:  2021-06-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.